deaths (OS)

Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)

versus placebo
nivolumab alone vs. placebo 1 1.0better0.35.096 %
nivolumab plus ipilimumab vs. placebo 1 1.0better0.35.079 %

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus etoposide plus platin
durvalumab plus etoposide and platin vs. etoposide plus platin 1 1.0better0.35.0100 %
durvalumab plus tremelimumab plus SoC vs. etoposide plus platin 1 1.0better0.35.098 %
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 1.0better0.35.0100 %
ipilimumab plus SoC vs. placebo plus SoC 1 1.0better0.35.079 %
pembrolizumab plus SoC vs. placebo plus SoC 1 1.0better0.35.098 %